Efficacy and safety of darunavir (Prezista(®)) with low-dose ritonavir and other antiretroviral medications in subtype F HIV-1 infected, treatment-experienced subjects in Romania: a post-authorization, open-label, one-cohort, non-interventional, prospective study.

Otilia Benea,Adrian Streinu-Cercel,Carmen Dorobat,Sorin Rugină,Lucian Negruţiu,Augustin Cupşa,Dan Duiculescu,Carmen Chiriac,Corina Itu,Liviu Jany Prisăcariu,Ionel Iosif

Efficacy and safety of darunavir (Prezista(®)) with low-dose ritonavir and other antiretroviral medications in subtype F HIV-1 infected, treatment-experienced subjects in Romania: a post-authorization, open-label, one-cohort, non-interventional, prospective study.

2014

Otilia Benea
Adrian Streinu-Cercel
Carmen Dorobat
Sorin Rugină
Lucian Negruţiu
Augustin Cupşa
Dan Duiculescu
Carmen Chiriac
Corina Itu
Liviu Jany Prisăcariu
Ionel Iosif

Introduction The aim of the study was to assess the safety and efficacy of darunavir (Prezista®) used in subtype F human immunodeficiency virus – type 1 (HIV-1) infected, antiretroviral therapy (ART)-experienced patients in Romania in routine clinical practice.

Keywords:

Clinical Practice
Cohort
Prospective cohort study
Immunodeficiency
Ritonavir
Darunavir
Physical therapy
Authorization
Pharmacology
Medicine
Vital signs
human immunodeficiency virus
Viral load
Adverse effect
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations